A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.
Public ClinicalTrials.gov record NCT00175825. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Double-blind, Randomized, Placebo-controlled, 4 Parallel Groups, Dose-ranging Trial Evaluating the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment at Doses of 5, 20 and 50 mg/Day in b.i.d. Administration (Oral Tablets of 2.5 or 10 mg) for a Maximum of 7 Weeks in Subjects From 16 to 65 Years With Refractory Epilepsy Suffering From Partial Onset Seizures Whether or Not Secondarily Generalized
Study identification
- NCT ID
- NCT00175825
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- UCB Pharma
- Industry
- Enrollment
- 210 participants
Conditions and interventions
Conditions
Interventions
- Brivaracetam Drug
- Placebo Other
Drug · Other
Eligibility (public fields only)
- Age range
- 16 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 6, 2005
- Primary completion
- Jun 28, 2006
- Completion
- Jun 28, 2006
- Last update posted
- Oct 1, 2018
2005 – 2006
United States locations
- U.S. sites
- 26
- U.S. states
- 23
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Phoenix | Arizona | — | — |
| Not listed | Little Rock | Arkansas | — | — |
| Not listed | Fresno | California | — | — |
| Not listed | Bradenton | Florida | — | — |
| Not listed | Jacksonville | Florida | — | — |
| Not listed | Chicago | Illinois | — | — |
| Not listed | Paducah | Kentucky | — | — |
| Not listed | Ruston | Louisiana | — | — |
| Not listed | Bethesda | Maryland | — | — |
| Not listed | Burlington | Massachusetts | — | — |
| Not listed | Grand Rapids | Michigan | — | — |
| Not listed | Rochester | Minnesota | — | — |
| Not listed | Tupelo | Mississippi | — | — |
| Not listed | Chesterfield | Missouri | — | — |
| Not listed | Great Falls | Montana | — | — |
| Not listed | Englewood Cliffs | New Jersey | — | — |
| Not listed | Toms River | New Jersey | — | — |
| Not listed | New York | New York | — | — |
| Not listed | Wilmington | North Carolina | — | — |
| Not listed | Columbus | Ohio | — | — |
| Not listed | Philadelphia | Pennsylvania | — | — |
| Not listed | Woonsocket | Rhode Island | — | — |
| Not listed | Greenville | South Carolina | — | — |
| Not listed | Dallas | Texas | — | — |
| Not listed | Houston | Texas | — | — |
| Not listed | Salt Lake City | Utah | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00175825, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 1, 2018 · Synced Apr 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00175825 live on ClinicalTrials.gov.